ReviewHistology and histopathology2022
Degenerative physiochemical events in the pathological intervertebral disc.
Review in Histology and histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Aggrecan and small leucine-rich proteoglycan fragments correlate with Toll-like receptor-2 mediated inflammation in painful degenerative disc disease.The Korean journal of pain · 2026Article
- Intervertebral disc anomaly intelligent classification system based on deep learning, IDAICS.Frontiers in radiology · 2025Article
- Serglycin secreted by late-stage nucleus pulposus cells is a biomarker of intervertebral disc degeneration.Nature communications · 2024Article
- Investigating the characteristics of mild intervertebral disc degeneration at various age stages using single-cell genomics.Frontiers in cell and developmental biology · 2024Article
- Single-cell RNA-seq analysis reveals that immune cells induce human nucleus pulposus ossification and degeneration.Frontiers in immunology · 2023Article
- Genipin Cross-Linked Decellularized Nucleus Pulposus Hydrogel-Like Cell Delivery System Induces Differentiation of ADSCs and Retards Intervertebral Disc Degeneration.Frontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Low back pain is one of the commonest musculoskeletal complaints that affects individuals of all ages and is a leading contributor towards work loss worldwide. The range of current treatment modalities involving surgeries, injectable agents, and medications is promising but cannot address the reasons behind the occurrence of pain in patients with degenerative disc pathologies. One possible factor for the limited success is the lack of evidence behind the identification of early, intermediate, and late stages of painful changes methodologically in a vast group of populations and the manifestation of the diseases in terms of increased physical activity, hereditary patterns, and various risk factors. However, despite these challenges, steady progress has been achieved in understanding the parameters in abnormally loaded progressively degenerating discs and these features have been elucidated at a physical, biochemical, and cellular level. These recent findings can likely lead to the development of therapeutic interventions that will identify and retard tissue damage, decrease pain, and improve the quality of life in these patients. Therefore, the main aim of this review is to integrate recent updates in intervertebral disc degeneration research for the development of evidence-based screening protocols and more targeted interventions in the management of low back pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.